Apexigen To Present At Upcoming Investor Conferences

SAN CARLOS, Calif., Feb. 19, 2019 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences:

Citi's 7^th Annual Immuno-oncology Leadership Summit
New York, NY
Tuesday, February 19, 2019 at 3:30 pm ET

SVB Leerink's 8^th Annual Global Healthcare Conference
New York, NY
Wednesday, February 27, 2019 at 2:10 pm ET

Cowen's 39^th Annual Healthcare Conference
Boston, MA
Tuesday, March 12, 2019 at 4:00 pm ET

William Blair's IO Conference
New York, NY
Thursday, March 21, 2019 at 2:05 pm ET

About Apexigen
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient's immune system to combat and eradicate cancer. APX005M and Apexigen's additional preclinical programs were discovered using APXiMAB™, Apexigen's proprietary product discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product candidates discovered using APXiMAB™ are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.

Apexigen Contact:
Mark Nevins
Vice President, Business Development
650-931-6236
[email protected]

SOURCE Apexigen, Inc.

Related Links

http://www.apexigen.com